Johnson & Johnson reported strong Q2 earnings, driven by a 41.1% year-on-year sales increase of its depression treatment Spravato, reaching $584 million. The company raised its 2026 adjusted diluted EPS guidance from $11.45-$11.65 to $11.6-$11.75, reflecting improved financial outlook. This positive performance led an analyst to upgrade J&J's stock rating from Sell to Hold, despite previous concerns over talc litigation and declining sales of other drugs. The upgrade suggests growing confidence in J&J's future earnings potential.
Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with dara...
Invesco's High Yield Equity Dividend Achievers ETF (PEY) uses a unique strategy by selecting stocks with at least 10 years of consecutive dividend growth before filtering for high yield. This approach avoids the pitfalls of pure yield-based ETFs that...
Johnson & Johnson shares trade near their 52-week high after a 55% rise, driven by strong revenue growth and promising drug sales. The company raised its full-year guidance, highlighting growth in key products like DARZALEX and TREMFYA. However, the ...
Fidelity Dividend ETF for Rising Rates (FDRR) targets dividend payers linked to 10-year Treasury yields but the rising rate environment ended in late 2025. The ETF's payout is safe, supported by cash-rich mega-cap companies like NVIDIA, Apple, and Mi...
A $300,000 investment in Vanguard High Dividend Yield ETF (VYM) ten years ago grew to about $922,110 with dividends reinvested, while the same amount in the S&P 500 reached roughly $1,063,230. VYM offers a lower yield around 2.2% and charges a 0.04% ...
